Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 30, 2006
Primary systemic therapy in operable breast cancer: clinical data and biological fall-outM Maur, V Guarneri, A Frassoldati, et al.
Archives of Environmental Contamination and Toxicology|May 1, 1997
The effects of used motor oil, silt, and the water mold Saprolegnia parasitica on the growth and survival of mole salamanders (genus Ambystoma)H Lefcort, K A Hancock, K M Maur, et al.
Pathologica|February 17, 2018
ALK-positive adenocarcinoma of the lung expressing neuroendocrine markers and presenting as a "pituitary adenoma"M C Mengoli, F Bertolini, M Maur, et al.
Bone Marrow Transplantation|July 27, 2004
HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell supportV Guarneri, C Bengala, C Orlandini, et al.
Lung Cancer (Amsterdam, Netherlands)|April 25, 2006
A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapyF Cappuzzo, S Novello, F De Marinis, et al.
European Journal of Cancer (Oxford, England : 1990)|July 22, 2008
Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumoursS Cresta, C Sessa, C V Catapano, et al.
British Journal of Cancer|June 16, 2005
Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancerF Cappuzzo, S Novello, F De Marinis, et al.
British Journal of Cancer|March 30, 2006
Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective studyC Bengala, C Zamagni, P Pedrazzoli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2009
Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxelC Sessa, D Tosi, L Viganò, et al.
Breast (Edinburgh, Scotland)|July 17, 2017
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA studyM E Cazzaniga, M Airoldi, V Arcangeli, et al.
Pageof 1